BCL2L11 and bladder transitional cell carcinoma: Among these treatments, Ipatasertib, an AKT kinase inhibitor, induces mitochondrial apoptosis in BLCA cells by upregulating Bim,[61] while ABT-737, a Bcl-2 family inhibitor, enhances apoptosis-inducing treatments by promoting necroptosis in urothelial cancer cells.[62] Conventional chemotherapy agents such as cisplatin, paclitaxel, vinblastine, and docetaxel showed increased sensitivity in the high-risk group.